NanoInterventions introduced the mouse stent model for rapid screening of new coronary stent therapeutics at the BIO International Convention held in San Diego this week.
The model, complete with a mini-stent that has the ability to replicate the human diseased vessel, represents a starting point in the development of next-generation drug-eluting stents (DES).
The Mouse Stent Model is a fast, predictive model of how a new therapeutic will affect the diseased human artery when implanted as part of a DES. The high-throughput system provides the ideal method to screen therapeutic leads advancing from pharmaceutical and biotech companies as well as university laboratories, the company said.
NanoInterventions, emerged from the strategic global partnership of the Brooklyn Park, Minn.-based Integra Group and Nanocopoeia of St. Paul, Minn. along with Stentome, with operations in Palo Alto, Calif.; Galway, Ireland; Oxford, England; and the University of Western Ontario, in London, Ontario.